Trial Profile
Evaluation of Vildagliptin (Galvus) as add-on to Insulin in Residual beta-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 13 May 2014 Planned end date changed from 1 Aug 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 13 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Mar 2012 New trial record